SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-18-0444
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Shipping Out MEK Inhibitor Resistance With SHP2 Inhibitors

Cancer Discovery
Oncology
2018English

SHP2 Inhibition Overcomes RTK-mediated Pathway Re-Activation in KRAS Mutant Tumors Treated With MEK Inhibitors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2012English

PAK Signaling Promotes Acquired Resistance to BRAF and MEK Inhibitors

Cancer Discovery
Oncology
2017English

MEK1 Mutations Confer Resistance to MEK and B-Raf Inhibition

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MEK Inhibition Prevents TGF‑β1‑induced Myofibroblast Transdifferentiation in Human Tenon Fibroblasts

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

Cancer Cell
Cancer ResearchOncologyCell Biology
2012English

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition

Clinical Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy